top of page
Search

UK MHRA Guidance: Apply for the Early Access to Medicines Scheme (EAMS)

Writer's picture: Sharan MuruganSharan Murugan
Aug 18, 20242 min read

The Medicines and Healthcare Products Regulatory Agency (MHRA) published guidance on "Apply for the early access to medicines scheme (EAMS)" on 16 August, 2024 that is designed to provide patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a full marketing authorization. This scheme is valuable when there is a clear unmet medical need, and the medicine in question shows promising results during early clinical trials.


For a medicine to be considered under EAMS, it must meet specific criteria:

  • The condition being treated is life-threatening or seriously debilitating.

  • There is a clear unmet medical need, meaning no satisfactory treatment is available, or the new treatment offers significant advantages over existing options.

  • Based on early clinical data, The medicinal product will likely offer major benefits to patients.

  • The company has demonstrated the intention to submit a marketing authorization application within a reasonable timeframe.


The application for EAMS is a two-stage process:

  • Step 1: Promising Innovative Medicine (PIM) Designation: The first stage involves obtaining a PIM designation, which indicates that the MHRA considers the medicine a promising candidate for EAMS. The PIM designation is based on preliminary data showing the potential for significant improvement in the treatment of a life-threatening condition.

  • Step 2: EAMS Scientific Opinion: After obtaining the PIM designation, the company can apply for a scientific opinion. This involves a more detailed assessment of the medicine’s quality, safety, and efficacy based on available data. The scientific opinion, if positive, allows the medicine to be made available to patients under EAMS.


The scientific opinion describes the risks and benefits of the medicine based on data gathered from the patients who will benefit from the medicine. The opinion supports the prescriber and patient to decide on whether to use the medicine before its licence is approved. If you want to apply for an EAMS scientific opinion from MHRA you must have a PIM designation.


A public assessment report (PAR) and the EAMS treatment protocol will be published on GOV.UK following a positive scientific opinion and the PAR will include:

  • how the product is used and how it works

  • summary of the key clinical studies

  • the risks and benefits of the product

  • the reason for the positive EAMS scientific opinion

  • any uncertainties

  • information about ongoing clinical studies

  • measures in place to monitor and manage risk


For more detailed information on the Early Access to Medicines Scheme (EAMS) and the application process, please refer to the official MHRA guidance.

17 views0 comments

Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page